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Objectives: The EuroScan International Network is a global network of publicly funded early awareness and alert (EAA) systems for health technologies. We describe the EuroScan
member agency systems and methods, and highlight the potential for increased collaboration.
Methods: EuroScan members completed postal questionnaires supplemented with telephone interviews in 2012 to elicit additional information and check equivalence of responses.
Information was updated between March and May 2013.
Results: Fifteen of the seventeen member agencies responded. The principal purpose of agencies is to inform decisions on coverage or reimbursement of health services and
decisions on undertaking secondary research. The main users of information are national governments; health professionals; health services purchasers, commissioners, and decision
makers; and healthcare providers. Most EuroScan agencies are small with almost half having fewer than two whole time equivalent staff. Ten agencies use both active and passive
identification approaches, four use only active approaches. Most start identification in the experimental or investigational stages of the technology life cycle. All agencies assessed
technologies when they are between the investigational and established, but under diffusion stages. Barriers to collaboration revolve around different system aims, purposes, and
requirements; a lack of staff, finance, or opportunity; language differences; and restrictions on dissemination.
Conclusions: Although many barriers to collaboration were identified, the majority of agencies were supportive of increased collaboration either involving the whole EuroScan Network
or between individual agencies. Despite differences in the detailed identification processes, members thought that this was the most feasible phase to develop additional collaboration.
Keywords: Early awareness and alert systems, Horizon scanning, Healthcare technology
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Early awareness and alert (EAA) systems are increasingly con-
sidered an essential component of health technology assessment
(HTA) and decision making around the evaluation, adoption,
and diffusion of emerging and new health technologies. Indeed,
with increasing deliberations regarding the benefits of early di-
alogue with industry, EAA systems remain at the forefront of
methodological developments in this area. The International In-
formation Network on New and Emerging Health Technologies
(the EuroScan International Network) is a global network of
publically funded, nonprofit making EAA systems for health
technologies (www.euroscan.org.uk). In 2012, the network up-
dated its aims and goals, and these now include the sharing of
skills and experiences, the continuing development of method-
ological approaches to EAA activities, and the on-going ex-
change of information about new and emerging health tech-
nologies. The exchange of information is facilitated by the use
of a web-based database which currently holds just over 2,500
entries. Almost 90 percent of information in the database is pub-
licly accessible, the rest containing commercially or politically
sensitive information.
A key activity for the network is the development and dis-
semination of methods including the setup and organization of
individual EAA systems and the detailed processes used within
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systems for identification, filtration and prioritization, assess-
ments, and dissemination. Information on these methods can be
found in the EuroScan methods toolkit (1). Previous compar-
isons of EAA systems and methods have looked at the systems
as a whole (2–6), reported on and summarized key methods
(7;8) or assessed specific aspects of the processes used, for ex-
ample, the identification, filtration, and/or prioritization of new
and emerging health technologies (9–12).
The comparative analysis of EuroScan International Net-
work agencies in 2008–09 found that fourteen of twenty agen-
cies who responded (70 percent) were set up to inform coverage
or reimbursement decisions and inform decisions about sec-
ondary research, 50 percent informed decisions about capital
or recurrent spending and seven (35 percent) informed deci-
sions about primary research (5). Detailed questions on meth-
ods found that fifteen agencies (75 percent) either relied on or
supplemented their identification with the ability to call for and
accept suggestions from individuals or organizations outside
their agency, eleven agencies (55 percent) used primary sources
available on the Internet for identification, and two agencies (10
percent) obtained information directly from commercial devel-
opers (2). Eighteen agencies (90 percent) had a formal filtration
process which was implemented by in-house staff in twelve (60
percent) agencies, by a scientific board in five (25 percent) agen-
cies, by the policy-making users in three (15 percent) agencies,
and by individual experts in two (10 percent) agencies. Eigh-
teen agencies (90 percent) reported using prioritization criteria
around patient numbers and burden of disease; clinical benefit;
economic impact; availability of evidence; current diagnostic,
therapeutic, or other management options; safety; and social,
ethical, and legal aspects. Agencies produced a range of out-
puts with the depth of assessments undertaken appearing to
relate to the time frame of reporting. Agencies investigating
technologies 2 to 3 years before launch were less likely to in-
clude evidence of clinical benefit in their reports than those
agencies investigating technologies nearer to product launch.
A systematic review of methods used for healthcare hori-
zon scanning undertaken by the Agency for Healthcare Re-
search and Quality (AHRQ) in a review of their horizon
scanning project, found twenty-three formal horizon scanning
programs, most of which are or have been members of the
EuroScan International Network, and several activities carried
out in the United States of America by both governmental or
nongovernmental agencies (8). Some of these activities were
commissioned by AHRQ from contractors such as the ECRI
Institute, others related to licensing agencies such as the US
Food and Drug Administration, and decision makers for fun-
ders of healthcare such as Medicare and Medicaid. Although
the authors identified a gap in evidence on detailed methods,
they report that the non-EuroScan projects had very different
goals, target technologies, and time horizons and used a variety
of methods for the identification and assessment of individual
technologies.
Although Wild and Langer’s overview of horizon scanning
systems, mentioned non-EuroScan agency horizon scanning ac-
tivity from organizations such as the ECRI Institute and Hayes
Incorporated, it only included details from the then, thirteen Eu-
roScan member agencies (6). Their review concluded that the
EuroScan members have a shared understanding of the activity
and used common terminology. The systems were found to dif-
fer in terms of their size, resources, operational level, mandate,
customers, and organizational embedding. These differences
led to a variation in the methods for the identification, filtra-
tion and prioritization, assessment, and dissemination of health
technologies.
Within the EuroScan International Network members were
aware of a similarity of purpose, identification sources, and
methods used between agencies, and because of constrained
health and research budgetswere conscious of the need to reduce
duplication if practicable, while maintaining individual agency
service and delivery aims and needs. The potential to increase
the quality of EAA outputs by closer collaboration was also an
important consideration.
OBJECTIVES
We aimed to update the comparative analysis undertaken in
2008/09 and describe the current EuroScan International Net-
work member agency EAA systems, to identify similarities and
differences, and highlight any opportunities for increased col-
laboration between member agencies or within the Network as
a whole.
METHODS
In December 2011, EuroScan International Network member
agencies were asked to complete a questionnaire about their
EAA system structure and funding; its purpose and coverage;
the methods used for identification, filtration, assessment, and
reporting; their use of clinical and scientific experts; and means
of dissemination. We also asked about existing collaborations
between members and/or with other nonnetwork organizations
and about any real and perceived barriers to collaboration.
Following the initial survey in December 2011, a semi-
structured telephone interview was undertaken with each par-
ticipant to clarify individual answers, to check their understand-
ing of the language used by and between members, and to elicit
additional opinions on how collaboration could be promoted
or assisted. The interviews were carried out between February
and May 2012 on Skype or ordinary telephone using predeter-
mined questions to guide the conversation. The material was
transcribed (http://scribie.com) and reviewed by the interviewer
(Rosimary Terezinha de Almeida) to verify accuracy and con-
sistency of the transcription. Results were incorporated into the
individual agency questionnaire information.
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All information was checked bymembers and a final oppor-
tunity given for updating information provided between March
and May 2013.
RESULTS
Of the seventeen EuroScan International Network members in
January 2013, fifteen supplied sufficient information either in
the initial questionnaire (December 2011), interview (February
to May 2012) and/or during the final updating (March to May
2013) for inclusion in the study. For a list of respondents and
their agency abbreviations, please refer to the acknowledge-
ments section.
Of the fifteen agencies, twelve were European and three
were from outside Europe (from Australia, Canada, and Israel).
Five were hosted by or were part of an HTA agency, six by
organizations involved in health policy/decision making or sup-
porting health policy, for example, health or other governmental
ministries, two by organizations involved in health research, and
one each by a hospital system and a university. Eleven systems
were funded by the national health system, department of health
or health services only, one from a regional health system only,
two from national and regional departments or health services,
and one from the host HTA agency. Agency staffing levels for
EAA activities varied from 0.15 to 21.5 whole time equivalents,
see Table 1.
Purpose, Customers, and Coverage
Figure 1 shows the main reported purposes of the EAA sys-
tems. Over three quarters of the agencies considered their main
purpose to be informing decisions on coverage or reimburse-
ment of health services and informing decisions on undertaking
secondary research, for example, health technology assessment
and systematic reviews. Many of the other purposes related to
decision making around the availability and adoption of new
health technologies and to inform primary research, that is, the
collection of original data for instance for clinical trials. Other
purposes included identifying technologies with legal or eth-
ical concerns, informing decisions about the development of
clinical guidance, developing forecasting models for drug uti-
lization and expenditure, and collaboration with international
organizations involved in drug evaluation.
Most agencies had more than one principal intended user
of their information. Thirteen agencies informed national gov-
ernmental health departments and ministers; twelve informed
healthcare professionals; eleven informed health service pur-
chasers, commissioners, or other decision makers; eleven in-
formed healthcare providers, for example, hospitals; seven in-
formed regional, state, or provincial government; six informed
national research and development programs; four informed
insurance or re-imbursement organizations; two informed con-
sumers of health services; and two informed other users includ-
ing an ombudsman, a national cancer care guideline program,
Table 1. Number of Staff, Types of Technologies Covered, and Use of Experts by 15
Responding Agencies
Number of agencies
Number of staff in EAA system
< 1 whole time equivalent staff 4
1 to<2 whole time equivalent staff 3
2 to<5 whole time equivalent staff 5
5 to<10 whole time equivalent staff 2
> 10 whole time equivalent staff 1
Types of technologies
Devices (includes imaging equipment) 13
Diagnostics (includes diagnostic and prognostic markers) 13
Interventional procedures 12
Pharmaceuticals (includes vaccines) 10
Programs e.g. screening or vaccination 10
Healthcare settings, e.g., organizational changes,
professional boundaries
8
Others 0
Stage of EAA activity supported by clinical and scientific experts
Topic identification 12
Topic filtration 6
Topic prioritisation 11
Early assessment 10
Report writing 10
Peer review 12
Other – information provision; follow-up of emerging
technologies.
2
Don’t use 0
a national council for quality and prioritization in health care,
and evaluation and guidance producers.
Four agencies covered all types of technologies (drugs, de-
vices, diagnostics, interventional procedures, programs, and
healthcare settings) and two covered all technologies except
healthcare settings. Table 1 shows the coverage of individual
technology types by agencies. In relation to the clinical areas
covered, fourteen EAA systems covered all disease areas, the
remaining system only considered oncology drugs.
Identification, Filtration, and Prioritization
In considering the potential to increase collaboration a variable
was created from member responses to categorize the principal
method of identification of new and emerging health technolo-
gies into active, passive or a combination: (i) Active: identi-
fication undertaken by an active search in several sources of
technology news, literature or by direct contact with the indus-
try. (ii) Passive: topics suggested or requested from experts,
government, patients or the public, board of advisers and/or
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Figure 1. Main purpose of EuroScan International Network member EAA systems.
industry application or notification. (iii) Combination: the use
of both active and passive methods.
Ten agencies used both active and passive identification
methods, four used only active methods (AETSA, IHSP, LBI-
HTA, NIHR-HSC), and one only passive methods (SBU). Nine
agencies commenced their identification process when tech-
nologies are in the “experimental” phase (phase I and II or
equivalent). Four started when the technologies are in the “in-
vestigational” phase (phase III or equivalent) and two when the
technologies are “nearly established” (some use outside clinical
trials, but not widely available). As agencies identified topics
in several of the development stages, identification by agencies
included the “experimental” phase in nine agencies, the “inves-
tigational” stage in thirteen agencies, the “nearly established”
phase in thirteen agencies, the “established under diffusion”
phase (used outside clinical trials, but not fully diffused) in ten
agencies, and “established” (full market use, but some contro-
versial issues remain) in eight agencies.
Thirteen agencies undertook in-house filtration and/or pri-
oritization. This was undertaken only in-house in four agencies,
in-house and in collaboration with experts in five agencies,
in-house and in collaboration with a scientific board in two
agencies, and in-house and in collaboration with both experts
and a scientific board in one agency. One agency used in-house
filtration and prioritization in collaboration with customers and
commissioners. One agency used only a scientific board for
both filtration and prioritization.
The filtration and prioritization criteria usedwithin the EAA
systems had common themes around (i) the patient group size
and burden of disease; (ii) the anticipated clinical benefits; (iii)
the presence of innovation and current alternatives; (iv) the po-
tential costs and organizational impact; (v) the likely diffusion,
timing, and regulation; (vi) any potential ethical, social, and
other impacts; and (vii) individual technology relevance and
potential interest to policy makers and health systems.
Assessment, Outputs, and Dissemination
Two agencies assessed technologies when they were in the “ex-
perimental” phase, nine when the technology was in the “inves-
tigational” phase, thirteen when the technologies were “nearly
established”, ten in the “established under diffusion” stage, and
eight when the technologies were “established” (Figure 2). Five
agencies produced their outputs in their first language (non-
English) only; three in English only; and seven in both the first
language and English.
Seven agencies produced short reports of one to four pages,
eight produced longer reports of four to ten pages, four pro-
duced comprehensive reports of over ten pages, and four agen-
cies produced other types of reports such as in-depth reviews of
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Figure 2. Stage in technology lifecycle for assessment, showing the first and last stages for the production of assessments.
emerging technologies across a patient pathway. Six agencies
produced an estimated one to ten reports per year, three between
eleven and twenty reports, three between twenty-one and fifty
reports, and two produced over fifty reports a year. Seven agen-
cies updated their reports, two occasionally updated, and five
did not update.
Eleven agencies included an assessment of a technology’s
potential for significant health service impact in their main
EAA-related output, thirteen included an assessment of safety
and efficacy, eleven of clinical effectiveness; and seven of cost-
effectiveness at least in some instances. Other areas included in
the main outputs were consideration of costs and other clinical,
patient and financial impact (five agencies), social, ethical and
legal impact (four agencies), regulatory status and stage of dif-
fusion (three agencies), innovation and place in therapy (three
agencies), and burden of disease, uncertainties, and trial quality
(one agency each).
Twelve agencies published their reports openly on their
agency website, seven in another “open” way, for example,
widely distributed newsletter or peer-reviewed journal, and ten
agencies mentioned the EuroScan database, as a means of dis-
semination. Three agencies published internally or to direct
customers/users only and six to health professionals.
Use of Experts
All fifteen agencies used experts at somepoint in their processes,
see Table 1 for details. Six agencies paid their experts and nine
do not. Those agencies that did pay varied in what they paid for:
one paid travel expenses only; three paid a fee and expenses for
travel; and two paid only a fee for assessment, peer review, or
report writing.
Collaboration
Eleven of the agencies loaded information about their identi-
fied or assessed new or emerging health technologies into the
EuroScan International Network web-based database. The pro-
portion of EAA system output in 2012 recorded on the database
from agencies that used it varied from 5 percent to 100 per-
cent. Seven agencies reported more specific collaboration with
other EAA agencies both inside and outside the EuroScan Inter-
national Network. This was for identification (four agencies –
Osteba, AETS, CADTH and SFOPH), prioritization (two agen-
cies – IHSP and SFOPH), assessment (four agencies – IHSP,
LBI-HTA, SBU, and SFOPH), dissemination (one agency –
SBU), and education (one agency – SBU).
Agencies that reported no collaboration gave the main rea-
sons as:
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Figure 3. Classification of EuroScan International Network member agencies by identification approach and format of principal output.
• Lack of financial or human resources (four agencies)
• Lack of opportunity (three agencies)
• Processes and methods that are specific to our agency (three agencies)
• Requirement of customers that may be different to that of other agencies
(one agency)
• Language barrier (one agency)
• The main focus of work probably differs from that of the other members
(one agency)
A classification of the agencies by identification approach
and the format of the principal output are shown in Figure 3.
DISCUSSION
Summary of Key Results
We found that the principal purposes of the EuroScan Inter-
national Network member EAA systems are to inform deci-
sions on coverage or reimbursement of health services and to
inform decisions on undertaking secondary research. As ex-
pected given these purposes, themain users of information from
the EAA systems were national governments and ministries;
health professionals; health services purchasers, commissioners
or other decision makers; and healthcare providers. Most of the
EuroScan agencies were small with almost half, at the time of
this survey, having fewer than two whole time equivalent staff.
All but one agency used active methods of identification
with all but two, starting identification in the experimental or
investigational stages of the technology life cycle. We found
that many agencies continue to identify technologies when they
are “established”, challenging the current boundaries of EAA
activity. This is however, consistent with the finding that many
EAA systems were an integral part of a HTA agency or an
organization carrying out HTA activities. In these cases the
function of the EAA system may not be as a separate entity
with specific outputs confined to information about a technology
before it has diffused.
Filtration and prioritization criteria were as anticipated and
similar between agencies. A key feature of the EAA systems
was the selection of the most significant health technologies so
that health service decision makers, HTA agencies, and others
can target their resources toward further research, evaluation,
and decision making. Experts participated in most system ac-
tivities except filtration, where only six agencies used them.
Clinical and scientific experts can provide essential insight into
the potential significance of new and emerging technologies and
their place in patient pathways and health services.
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We report a variable use of the EuroScan International Net-
work web-based database as a means of collaboration and dis-
semination, with some agencies not using the database to share
information and, of those that did use it, a number who only add
a small percentage of their final outputs. Barriers to current and
future collaboration revolved around the different system aims,
purposes and requirements; a lack of staff or finance; a lack of
opportunity; language differences; and restrictions on dissem-
ination such as those imposed by required or imposed system
confidentiality. Some of these barriers may be insurmountable
especially in the financial situation that many health systems
find themselves.
In summary the systems had common purposes, overlap-
ping timeframes for identification, similar filtration criteria but
variable commitments to sharing and collaboration.
Strengths and Limitations
Although not all EuroScan InternationalNetworkmembers took
part in the study, the collaboration represents the largest net-
work for health technology, government-related EAA systems
and these results represent the global spread of the member
agencies. It is unlikely that significantly different experiences
and methods have been missed, although some of the detailed
application of methods in the nonresponding systems may be
different. The interview process in 2012 was resource intensive,
but was a good way to clarify some of the answers given in the
initial questionnaires and, for nonresponders to the initial ques-
tionnaire, a means of gaining information. The study included
both the strategic context and organization of EAA systems and
represents a good starting point for agencies and organizations
who wish to establish new or review current EAA systems.
Comparison with other Studies
The results presented here do not differ significantly from those
reported from the 2008–09 survey (4;7). This is not unex-
pected because the members of EuroScan have not significantly
changed in the last 5 years. We do however, report more de-
tail on the time frame for the principal EAA activities of early
identification and assessment, which is valuable information
that can be used to increase understanding of each others’ sys-
tems and perhaps to indicate areas that are ripe for increased
collaboration.
Conclusions and Policy Implications
Although many barriers to collaboration were identified, the
majority of agencies were supportive in principal, of consid-
eration for increased collaboration either involving the whole
EuroScan International Network or between individual member
agencies.Many agencies however, reported that theywere not in
a stable position and/or that their work was not fully supported
by policy makers or funders in their own countries. This has
led directly to changing levels of available personnel, which is
a significant obstacle to increased collaboration which requires
time, understanding, energy, continuity, and finance.
Despite differences in the detailed identification processes,
during discussions following the survey members recognized
this stage as the most feasible phase to develop a formal col-
laboration between members. Indeed from a reduction in du-
plication viewpoint the identification stage is the most obvious
area where closer collaboration could bring benefits. However,
full use of the principal means of information exchange, the
EuroScan web-based database, remains variable and is reported
as difficult for many agencies. Some of the reported constraints
could be overcome with an increase in support, with any in-
crease in information exchange being of benefit to all members
and their associated health systems. One aspect of closer col-
laboration not mentioned by any member in the survey is that of
trust. If truly collaborative identification of emerging technolo-
gieswas piloted between countries with different agencies being
responsible for specific identification sources, then an agency
would not be in complete control of the supply of information
needed to perform their own role or fulfil their contract. This
would lead to an uncertainly of the ability to deliver timely and
comprehensive information. This may be an important reason
why a cross-national collaborative identification program has
not been progressed.
EAA systems are well placed to support early dialogue be-
tween manufacturers, evaluators and health services, by iden-
tifying technologies and their developers before evidence has
been generated. Given their role and place in decision making,
continuing investment in these systems is important.
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